Skip to main content

Table 4 Cox analyses of overall survival for breast cancer patients receiving NACT

From: ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc

Factors Univariate analysis Multivariate analysis
p-value HR (95%CI) p-value HR (95%CI)
ADAM10 (Pre-NACT) 0.147 1.90 (0.80–4.52) 0.028* 3.67 (1.15–11.70)
ER 0.359 0.84 (0.57–1.23) 0.253 0.68 (0.35–1.32)
PR 0.246 0.72 (0.41–1.26) 0.982 0.99 (0.45–2.19)
HER2 0.727 0.86 (0.37–1.99) 0.531 0.73 (0.28–1.94)
Ki67 0.199 1.80 (0.73–4.43) 0.049* 3.33 (1.01–10.99)
Age 0.16 0.54 (0.23–1.28) 0.553 0.74 (0.27–2.01)
BMI 0.35 1.48 (0.65–3.36) 0.716 0.83 (0.31–2.25)
Histological grade 0.830 1.13 (0.38–3.31) 0.112 2.85 (0.78–10.37)
Tumor size 0.002** 4.11 (1.69–10.03) 0.045* 2.84 (1.02–7.88)
Distant metastasis 0.602 0.59 (0.08–4.36) 0.528 0.51 (0.06–4.15)
Lymphatic metastasis 0.011* 3.66 (1.35–9.94) 0.002** 8.13 (2.10–31.43)
Response to NACT 0.082 0.48 (0.21–1.10) 0.993 1.00 (0.38–2.67)
  1. *p < 0.05, **p < 0.01